Selank: What the Research Shows

Medically reviewed by Mark Strehlow, MD, Medical Director — November 2026

Selank is a synthetic peptide built in Russia on tuftsin, a peptide the body makes; Russian drug references list it as a registered medicine there, nasal drops for anxiety, and it is sold online as a nasal spray or an injection for anxiety, stress and focus. Tested in people, in small Russian studies with no placebo group: anxiety scores fell over two weeks in patients given selank, and in the one head-to-head trial read in full, the anxiety subscale had fallen by 26.3% on selank and by 55% on the benzodiazepine phenazepam by day 14. The evidence stops at about 200 patients treated for 14 to 30 days: no placebo-controlled treatment trial was found, and no study in people of injected selank, of the modified versions sold online, or of use beyond 30 days.

This review, part of our peptide library, sets out what has been tested and what hasn’t. Our providers prescribe some of the peptides reviewed in this library, and we earn money from that care.

At a glance

FDA status
Not FDA-approved, and outside the FDA’s and HHS’s compounding policies.
Evidence in people
About 200 patients in seven small studies of 14 to 30 days; no placebo-controlled treatment trial found.
The claim you’ve heard
Benzodiazepine-strength: overstated. One trial’s anxiety subscale fell 26.3% on selank, 55% on phenazepam, by day 14.
Doses tested in people
1.8 to 2.7 mg a day for 14 days, by nose where stated. No injected dose was found.
Sport
Not named on WADA’s 2026 or 2027 List. WADA says an unnamed peptide “may still be prohibited”.

What selank is

Selank is a chain of seven amino acids (Thr-Lys-Pro-Arg-Pro-Gly-Pro), also written TP-7: tuftsin, a four-amino-acid peptide the body makes, with three more added. Its manufacturer says it was developed at two Russian institutes, the Institute of Molecular Genetics and the V.V. Zakusov Research Institute of Pharmacology.

In Russia. Russian drug-reference sites and the manufacturer report that selank is registered there as 0.15% nasal drops for adults with “anxiety states”, sold without a prescription. (Quotations from Russian sources are our translations.) We could not open Russia’s state register, so every line here about the registration and the label is second-hand, and the copies differ on some points. We found no record of approval by a regulator outside Russia.

Online. “N-acetyl selank”, “selank amidate” and “N-acetyl selank amidate” are different molecules, with one or both ends chemically capped. No study of any of them was found, in people, animals or cells, and nothing known about selank counts as evidence for them. Selank is also sold as a powder for injection; every treatment study in people that we read gave it into the nose or did not state the route.

Where it stands with the FDA

Status checked: November 19, 2026.

In plain words: selank is not an FDA-approved medicine, and it is not on the FDA’s list of ingredients that can be used in compounding (making a medicine for one patient on a prescription). It is not among the six peptides in a draft compounding policy from HHS, the federal department the FDA belongs to, and the FDA says it lacks important safety information about selank in people.

As of November 19, 2026, selank is not an FDA-approved drug and is not on the FDA’s list of bulk drug substances that can be used in compounding under section 503A. It is in none of the categories of the FDA’s interim compounding policies and is not one of the six peptides named in HHS’s October 2026 draft interim policy; the FDA’s guidance says a drug compounded from a substance in this position “is not eligible for the exemptions in section 503A and may violate the FD&C Act”, and the FDA says it “lacks important information regarding any safety issues raised by selank acetate administered to humans.”

Section 503A is the compounding section of the federal Food, Drug, and Cosmetic Act (the FD&C Act). No federal source we read treats a nasal form of selank differently from an injected one. A registration in Russia is a fact about Russia; it is not FDA approval.

The FDA’s own entry. The FDA lists “Selank acetate (TP-7)” among “Bulk drug substances nominated but withdrawn”. A nomination withdrawn by the nominator is not an FDA judgment on selank, but it leaves selank in none of the FDA’s compounding categories and does not make it eligible. The entry adds: “Compounded drugs containing selank acetate may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation and peptide-related impurities” (immunogenicity: an immune reaction to the peptide; aggregation: molecules clumping together). We found no FDA evaluation of selank and no advisory-committee review.

HHS’s draft interim policy. On October 30, 2026, HHS announced a draft interim policy; in announcing it, HHS said it “does not intend to take enforcement action” against a state-licensed pharmacy compounding with one of six named peptides when its conditions are met. Selank is not one of the six, and the policy is not FDA approval.

Warning letters. None of twelve FDA letters to online peptide sellers opened for this review names selank. Two older letters to compounders, from 2020 and 2021, do; both predate the FDA’s current page.

Sport. Selank is not named on WADA’s 2026 or 2027 Prohibited List. Class S0 prohibits “Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use”; no source we read says whether WADA counts a registration in one country as such an approval. WADA’s note to the 2027 List says: “Even if a peptide is not specifically named on the List, utmost caution should be taken as it may still be prohibited and may be harmful to health.”

Claims you’ll see, and why sources disagree

Pages about selank disagree for three reasons.

  • We could read the most-cited trial only as an abstract, which calls the effects of selank and the benzodiazepine medazepam on anxiety “similar” and gives no scores.
  • Citations don’t say what the sentence says. A 2026 review states that “intranasal Selank has been tested in patients with mild generalized anxiety disorder”, with lower anxiety scores after two weeks, and cites a rat study for it.
  • Animal findings and other molecules stand in for selank in people. Claims about BDNF (a nerve growth factor) and “stress resilience” rest on rats, and sellers list selank beside N-acetyl and amidated versions for which no study was found.

Where this review says “not tested in people”, that is not the same as “doesn’t work”. It cuts both ways: not shown to help, and not shown to be safe.

Claim Level of evidence Verdict
“anxiolytic effects comparable to benzodiazepines” (anxiolytic: anxiety-reducing) Tested in people: open-label comparisons, no placebo Overstated. One abstract says “similar”; in the trial read in full the anxiety subscale had fallen 26.3% on selank and 55% on phenazepam by day 14.
No sedation, dependence or withdrawal Tested in people: open-label trials of 14 days, plus one week of observation Fewer benzodiazepine-type side effects than on phenazepam were reported, without blinding. Dependence: not established; no long-term or abuse-liability study was found.
“approved as a prescription medication in Russia for anxiety and cognitive enhancement” Russian product information, read second-hand Partly accurate. Listed as registered for anxiety states and stress disorders, and sold without a prescription. Cognitive enhancement is not a listed use, though the label’s account of how it works claims better memory and attention, citing no study.
“Increases BDNF levels to support learning and memory” Animal studies Rats only; in alcohol-exposed rats selank prevented a rise in BDNF. No study of memory or focus in healthy people was found.
Injections work; the N-acetyl amidated version is “the most stable and bioavailable form” None found No study in people of injected selank was found, and no study of either modified molecule in any species.
Safe, with practically no side effects Tested in people: about 200 patients, 14 to 30 days Not established. No serious adverse event is mentioned in anything read; adverse events were tabulated in only two papers.

What the evidence consists of

Nearly all of it is Russian, and most of it we could read only as abstracts. “Open-label” means patients and doctors knew who was getting what.

Tested in people

No placebo-controlled treatment trial was found.

Study People Design What happened Funding or limits
Zozulia, 2008 62: generalized anxiety disorder and neurasthenia Selank (30) against medazepam (32); indexed by PubMed as randomized Effects on anxiety “were similar”; no scores given Abstract only: dose, length and blinding unknown
Medvedev, 2014 60: phobic-anxiety or somatoform disorders Open-label; described as randomized, method not given; selank (30) against phenazepam (30), 14 days Behind phenazepam at day 14 on two measures (below) Read in full; supported by the manufacturer
Medvedev, 2015 70: the same diagnoses Open-label, as above; selank plus phenazepam (40) against phenazepam alone (30), 14 days Responders at day 14: 40% against 23% (p=0.14, not significant); 75% of the 20 who continued selank to day 21, against 30% on phenazepam alone Read in full; supported by the manufacturer; nothing on selank alone
Verbenko and Shakina, 2019 55 starting the antidepressant escitalopram Selank added (35) or not (20), 14 days; allocated “by a randomized blind method”, who was blind not stated “complete resolution of anxiety symptoms” in 89% against 15%; no visit or statistical test given Read in full; unequal groups; no placebo
Verbenko and Verbenko, 2018 30: adjustment disorder Selank for two weeks (15) against no treatment (15); randomization not mentioned Lower symptom-questionnaire scores two weeks later; the groups differed at the start No anxiety scale; an earlier report, apparently of the same patients, says 30 were treated
Pogodina and Nikiforova, 2024 64: asthenia (fatigue) after COVID-19 Selank plus three other drugs (32) against those drugs alone (32), 30 days; allocation not stated “a good effect”; no numbers Abstract only

The head-to-head trial (Medvedev, 2014). By day 14, when treatment ended, anxiety on the anxiety subscale of the scale the paper calls HDRS (it describes the Hospital Anxiety and Depression Scale) had fallen by 26.3% on selank and by 55% on phenazepam; the text gives no p value. Five patients on selank and 14 on phenazepam were rated markedly improved (CGI-I), and 5 against 7 were responders (a 50% fall in the total score); clinician-rated severity (CGI-S) changed alike in the two groups, and a quality-of-life score improved more on selank (43.3% against 3.1%). A week after both drugs were stopped, with the benzodiazepine’s effect wearing off, there were 17 responders on selank and 9 on phenazepam (p=0.037).

What these studies can’t tell us is whether selank works better than a placebo. With no blinding confirmed and outcomes rated by patients and clinicians, the falls in score can’t be separated from expectation, natural improvement and the other medicines given.

Reported in people

A 2012 conference abstract from the developers’ pharmacology institute describes 20 patients with generalized anxiety disorder given selank with no comparison group: mean Hamilton anxiety scores fell from 20.3 to 7.0 by day 3 in the 40% it calls “rapid responders”, and from 16.1 to 6.2 by day 14 in the rest.

A September 2026 preprint (not peer-reviewed; abstract read) pooled US clinical notes on 27 confirmed users of selank and 22 of semax, a related Russian peptide: 16 of the 49 (33%) reported a positive response. Its authors write: “This study is not designed to evaluate the effectiveness or harm of Semax or Selank.”

No case report, of benefit or of harm, was found.

Animal studies

  • Anxiety. Less anxiety-like behaviour in an anxious mouse strain (BALB/c), and no effect in a low-anxiety strain (C57BL/6).
  • Learning. Better learning in rats “with initially poor learning ability” and after experimental brain injury.
  • Route. In mice, the same dose changed different brain receptors by injection and by nose.
  • Toxicology. Repeat-dose, reproductive and cancer studies were not found in the published literature.

Lab studies and how it is thought to work

No mechanism has been established in people.

  • Enkephalins (lab studies). In human serum and plasma in the test tube, selank slowed the enzymes that break down enkephalins, the body’s opioid-like peptides, at 15 to 20 micromolar. No published study of the concentration it reaches in human blood was found.
  • GABA (lab studies). Selank changed how GABA, an inhibitory nerve signal, binds its receptor in brain-cell membranes, which the authors offer as a hypothesis; in a human cell line, selank alone changed the activity of none of the genes studied.
  • Measured in people. An enkephalin marker, blood cytokines (immune signals), the EEG (a brain-wave recording) and, in 52 healthy volunteers given selank, semax or placebo once, connections on a brain scan changed. That shows selank does something measurable, not how it would reduce anxiety.

Who produced the research

  • Of 78 PubMed records read, 37 (47%) carry N.F. Myasoedov of the Institute of Molecular Genetics as an author; Peptogen, which makes the Russian product, says that institute took part in creating the company.
  • Of the seven treatment studies, four come from the developers’ institutes or had the manufacturer’s support, two share an author who gave the manufacturer as her affiliation in 2017, and one shows no link in what we read.
  • No trial of selank was found in ClinicalTrials.gov or the EU’s register.
  • No experiment by a group with no apparent link to the developers was found.

Dosing: what has been tested, what is used, and what the reasoning supports

This section reports and reasons; it recommends nothing. No study comparing two doses of selank in people was found, so no dose can be called optimal.

Doses tested in people

Every amount in the studies we read was given into the nose or by a route the paper does not state. The two Medvedev trials state 2.7 mg a day for 14 days (21 days in 20 patients), without the route or the number of doses a day. The conference abstract states “2700 µg/day intranasally” and a “single dose (900 µg)” (µg: micrograms). The trial alongside escitalopram states 1.8 mg a day as nasal drops, six times a day for 14 days. The 30-day study gave nasal drops four times a day and states the amount only in drops.

No study in people of an injected dose, or of a dose by mouth, was found; the brain-scan abstract says “injection” without saying where or how much.

Doses in common use

These are amounts in circulation: practice that no trial set, reported so that a reader can see where each comes from and how it compares with what was studied.

  • Smaller amounts into the nose. A telehealth company’s marketing article states “750 to 1,500 mcg per day total, split across two or three intranasal administrations” (mcg: micrograms). No human study was found behind it; the range is 28% to 56% of the 2,700 micrograms (2.7 mg) a day the trials state.
  • A once-daily injection under the skin. The same company’s peptide page states “250-500 mcg subcutaneously once daily”, and a seller’s help article “300–500 mcg once daily subcutaneously”, in “4-week cycles with 4-week breaks”. No study in people of injected selank was found, and none of any cycle, so there is nothing to compare these with.
  • The modified versions. The marketing article says of N-acetyl selank amidate, “Same microgram ballpark per dose.” No study of it was found in any species; the numbers are borrowed from a different molecule.
  • The Russian label. A drug label, read from reference sites’ copies: three times a day into the nose for 14 days, repeatable after one to three weeks “after consulting a doctor”. It states the amount only in drops and prints no milligram or microgram figure, and we do not work one out. Its 14-day course matches the trials.

What the pharmacology supports, and what it doesn’t

  • Amount (not measured in people). No published study reporting a blood level of selank in people was found, after any dose by any route. The pharmacology supports no particular amount.
  • Frequency (claimed and not confirmed; then inferred). The Russian label, as reproduced, says the blood level falls over 5 to 5.5 minutes after a nasal dose, without saying whether that was measured in people or animals; no published measurement was found. If it is right, any real effect must outlast the peptide, as its developers argue: in the head-to-head trial the effect was still present 7 days after stopping. That settles no schedule: the label says three times a day, one trial used six, and no study comparing once a day with three times was found.
  • Route (measured in animals; then inferred). Because injected and nasal selank acted differently in mice, results from nasal drops say nothing reliable about injected selank, for benefit or for safety.
  • Duration (measured in people; convention). Studied for 14 to 30 days. Cycles of weeks to months are convention.
  • Monitoring (inferred). None has been established; the trials used symptom scales and a side-effect checklist. By inference: the symptoms themselves, with a defined stopping point, the nose, and allergic reactions.

Nobody knows what level a dose produces in a person’s blood or brain, or what injected selank or the modified versions do in people.

What common protocols get wrong

  • The trial amounts are understated. The marketing article presents its 750 to 1,500 micrograms a day as “What the Russian Clinical Data Actually Says” and names no study; the trials state 2.7 and 1.8 mg a day.
  • Sources that don’t support the page. The seller’s help article cites Russian trials of “intranasal Selank”, then gives only an injected regimen. The telehealth company’s page supports its benzodiazepine comparison with a PubMed number that belongs to a 2008 paper on a gene family.
  • Human research that isn’t. The marketing article attributes “up to 2,250 mcg per day during acute withdrawal phases” to “Russian addiction research”; the withdrawal studies found are in rats.
  • A conversion nobody can check. A protocol-aggregator page gives a microgram total for the Russian label’s regimen from a per-drop figure that the label, as reproduced, does not print. We could not verify it and do not repeat it.

The dose is the prescriber’s decision for one patient.

Safety, and who should be most cautious

In the studies. In the one trial of selank on its own read in full, the most pronounced side effect was a dry nose; the frequencies are in tables we could not read. The Russian label, as reproduced, adds allergic reactions, “including delayed”, and an unpleasant taste. No serious adverse event or death is mentioned in anything we read, and no case report of harm was found. That reflects the size of the evidence: about 200 patients, 14 to 30 days, adverse events tabulated in only two papers, and no post-marketing safety study found.

Outside the studies. The US preprint described above recorded “isolated dyspnea, palpitations, flushing, and emergency department visits” during periods of reported semax or selank use (dyspnea: shortness of breath). It pools the two peptides and was not designed to judge harm.

Dependence. The Russian label says selank “does not cause drug dependence or habituation”. In people that rests on 14 days of treatment and one more week of observation. A 2021 US pharmacology review (abstract read) calls phenibut and selank “poorly studied Russian drugs with GABAergic mechanisms that are inexplicably sold to US consumers as dietary supplements”.

Theory, labelled as theory. On reasoning alone, the people with most reason for caution are those taking opioid medicines or blood thinners, and anyone using an injected product. Selank slowed enkephalin-degrading enzymes in human blood samples and altered morphine withdrawal in rats; it had an anticoagulant effect in a lab clotting test; given into a vein, it briefly lowered blood pressure in anaesthetized cats. No human interaction, clotting or blood-pressure data were found.

Situation What is known Basis
Pregnancy, breastfeeding No human data were found. Contraindicated on the Russian label “because clinical studies have not been done” Russian label (reference copies)
Under 18; over 55 No study was found. The Russian label contraindicates use under 18 Russian label (reference copies); trial reports
Cancer, now or in the past No human data were found Searches for this review
Opioid medicines; blood thinners No human interaction study and no human clotting data were found Theory, above
Sedatives, alcohol With phenazepam, one open-label trial of 40 patients reported fewer benzodiazepine side effects, not more. No human study with alcohol was found One trial; searches for this review
Past substance dependence; other psychiatric or serious physical illness Excluded from the two Medvedev trials Trial reports
Injected selank; the modified versions No human safety data of any kind were found. The FDA’s concern names “certain routes of administration” Searches for this review; the FDA’s entry
Tested athletes Not named on WADA’s Lists; WADA urges “utmost caution” WADA

Product quality

  • Specifications. The registered Russian nasal solution is the only selank preparation found with regulatory specifications; nothing published says how stable selank is in the powders and sprays sold online.
  • Seized products. Belgium’s public-health institute identified selank and semax in two seized preparations and called such peptides “potentially dangerous molecules”. Its abstract gives no purity or contamination results.
  • US products. No published analysis of the purity, content, sterility or endotoxin level of selank sold as “research use only” was found. Of such labels the FDA wrote, in an August 2026 letter to an online peptide seller that does not name selank: “evidence obtained from your website establishes that your products are intended to be drugs for human use.”

What we make of it

This section is our reading of the evidence. It is a judgment, not a finding.

On the evidence, selank is unproven and experimental. For anxiety, a benefit is plausible: scores fell over two weeks in patients given it, the side effect reported was a dry nose, and the animal work points the same way in anxious strains. But no treatment study we found had a placebo group, and in the one head-to-head trial read in full selank was behind a benzodiazepine at the end of treatment. A fall in scores in an open-label study is what a helpful medicine would produce; expectation and time produce it too.

The claims run well ahead of that: benzodiazepine strength, sharper thinking in healthy people, “no dependence”, injections, modified versions and cycles lasting months. The record is itself a reason for caution: nearly half the published papers carry one developer’s name, the manufacturer supported two of the three trials we read in full, and we found no registered trial and no repeat of the work by a group without a link to the developers. That does not make the findings wrong; it means they stand untested by anyone else.

What would have to be true: that selank reduces anxiety more than a placebo in a blinded trial run by an independent group, and that the products sold here, by the routes they use, are the ones studied.

For whom selank might ever be considered, after what, with what monitoring and when to stop are our Medical Director’s to state.

Peptide care at Rock Creek Wellness

Our peptide care starts with lab tests and a visit with one of our providers. The provider decides whether any peptide suits you, and which one; you don’t choose from a menu. How that care works is set out on our peptide therapy page, along with the other reviews in this library. What Peptide Care costs is on the same page.

So that you can weigh this review knowing our interest: RCW’s providers prescribe some of the peptides reviewed in this library, and RCW earns money from that care.

What would change this review

  • A placebo-controlled, blinded trial. None was found in ClinicalTrials.gov or the EU’s register (searched November 19, 2026).
  • Studies in people of blood levels after a dose, of injected selank, or of the modified versions.
  • Sources we could not read: Russia’s state register, the 2008 trial’s full text and five clinical reports known only as citations.

Common questions

Does selank work for anxiety?

That has not been established: no placebo-controlled treatment trial was found. In small Russian studies anxiety scores fell over two weeks in patients given selank, but without a placebo group or confirmed blinding the falls can’t be separated from expectation and natural improvement.

Is selank safe?

That is not established. No serious adverse event is mentioned among about 200 patients followed for 14 to 30 days, but no study beyond 30 days was found, and no human safety data were found for injected selank or the modified versions.

Is selank FDA-approved?

No. It is not on the FDA’s list of substances for compounding either, and it is not among the peptides in HHS’s draft policy.

Can a doctor prescribe selank?

The federal sources we read give no yes or no about prescribers: their conditions attach to compounding and to the product. Selank is not FDA-approved, so a prescription would be for a compounded medicine, and the FDA’s guidance says a drug compounded from a substance in its position “is not eligible for the exemptions in section 503A and may violate the FD&C Act”. State pharmacy rules apply separately.

How much selank do people take, and how often?

The published studies state 1.8 to 2.7 mg a day for 14 days, by nose where the route is stated. Sellers’ pages state smaller amounts by nose and once-daily injections, which is practice no trial set; no study in people of injected selank was found, and none comparing doses or schedules. The dose is the prescriber’s decision for one patient.

Sources

Show all 57 sourcesHide sources
  1. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. US Food and Drug Administration, 2026.
  2. Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act. US Food and Drug Administration, 2025.
  3. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (notice of availability, 91 FR 68526, FR Doc. 2026-22192). Federal Register, 2026.
  4. HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. US Department of Health and Human Services, 2026.
  5. Warning letter: Tailor Made Compounding LLC, MARCS-CMS 594743. US Food and Drug Administration, 2020.
  6. Warning letter: Advanced Nutriceuticals, LLC dba The Guyer Institute of Molecular Medicine, 615908. US Food and Drug Administration, 2021.
  7. Warning letter: Peptide Partners LLC, 735063. US Food and Drug Administration, 2026.
  8. FDA’s warning-letter pages (twelve letters to online peptide sellers, dated December 2024 to August 2026, opened and searched). US Food and Drug Administration, 2026.
  9. WADA 2026 Prohibited List. World Anti-Doping Agency, 2025.
  10. WADA 2027 Prohibited List. World Anti-Doping Agency, 2026.
  11. Summary of Major Modifications and Explanatory Notes, 2027 Prohibited List. World Anti-Doping Agency, 2026.
  12. Selank (PubChem CID 11765600). US National Library of Medicine, PubChem, read 2026.
  13. Селанк® (капли назальные, 0.15%): инструкция по медицинскому применению, РУ № ЛП-№(010951)-(РГ-RU). Регистр лекарственных средств России (RLS), a Russian drug-reference site’s copy of the product instructions, 2025.
  14. Селанк® (Selank), капли назальные 0.15%. Справочник Видаль (Vidal Russia), a Russian drug-reference site, read 2026.
  15. Селанк – инструкция по применению (регистрационный номер ЛРС-003338/09). МЕДИ РУ, a copy of the earlier product instructions, 2011.
  16. «Селанк» – инновационный препарат для регуляции мозговых функций. АО «ИНПЦ «Пептоген» (the manufacturer), read 2026.
  17. Селанк стал безрецептурным препаратом. АО «ИНПЦ «Пептоген» (the manufacturer), 2017.
  18. ClinicalTrials.gov, search for “selank”. US National Library of Medicine, searched 2026.
  19. EU Clinical Trials Register, search for “selank”. European Medicines Agency, searched 2026.
  20. PubMed searches. US National Library of Medicine, searched 2026.
  21. Europe PMC searches. Europe PMC, searched 2026.
  22. [Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2008.
  23. Сравнение анксиолитического эффекта и переносимости селанка и феназепама при терапии тревожных расстройств [A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders]. Журнал неврологии и психиатрии им. С.С. Корсакова (Media Sphera), 2014.
  24. Оптимизация терапии тревожных расстройств пептидным препаратом селанк [Optimization of the treatment of anxiety disorders with selank]. Журнал неврологии и психиатрии им. С.С. Корсакова (Media Sphera), 2015.
  25. [Immunomodulatory effects of selank in patients with anxiety-asthenic disorders]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2008.
  26. P-1114 – Rapid and slow response during treatment of generalized anxiety disorder with peptide anxiolytic selank. European Psychiatry, 2012.
  27. Новые возможности потенцирования действия селективных ингибиторов обратного захвата серотонина регуляторным пептидом Селанк при терапии тревожно-депрессивных расстройств [New possibilities for potentiating the effects of antidepressants of the group of selective serotonin reuptake inhibitors by the regulatory peptide Selank in the treatment of anxiety and depressive disorders]. Врач (Vrach), 2019.
  28. The effectiveness of selank in the treatment of adjustment disorder. Psychosomatic Medicine and General Practice, 2018.
  29. Особенности анксиолитического и стрессопротективного действия пептидного препарата Селанк® при терапии расстройств адаптации и посттравматического стрессового расстройства. Медицинский алфавит (Medical alphabet), 2017.
  30. Постковидный синдром: возможности терапии астенических нарушений препаратом Селанк. Врач (Vrach), 2024.
  31. Functional Connectomic Approach to Studying Selank and Semax Effects. Doklady Biological Sciences, 2020.
  32. Increasing Direct-to-Consumer Use of Semax and Selank Peptides Decoded from LLM-Curated Clinical Notes and Physician Adjudication. Preprints.org (a preprint, not peer-reviewed), 2026.
  33. The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity. Bulletin of Experimental Biology and Medicine, 2001.
  34. [Semax and selank inhibit the enkephalin-degrading enzymes from human serum]. Bioorganicheskaia khimiia, 2001.
  35. [Leu-enkephalin homogeneously labeled with tritium in studying the Selank inhibiting effect on the enkephalin-degrading enzymes of human plasma]. Bioorganicheskaia khimiia, 2004.
  36. GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells. Frontiers in Pharmacology, 2017.
  37. Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity. Protein and Peptide Letters, 2018.
  38. Effects of Selank on behavioral reactions and activities of plasma enkephalin-degrading enzymes in mice with different phenotypes of emotional and stress reactions. Bulletin of Experimental Biology and Medicine, 2002.
  39. [The anxiolytic action of an analog of the endogenous peptide tuftsin on inbred mice with different phenotypes of the emotional stress reaction]. Zhurnal vysshei nervnoi deiatelnosti imeni I P Pavlova, 1998.
  40. [Experimental optimization of learning and memory processes by selank]. Eksperimental’naia i klinicheskaia farmakologiia, 2010.
  41. The optimizing action of the synthetic peptide Selank on a conditioned active avoidance reflex in rats. Neuroscience and Behavioral Physiology, 2003.
  42. Use of Selank to correct measures of integrative brain activity and biogenic amine levels in adult rats resulting from antenatal hypoxia. Neuroscience and Behavioral Physiology, 2008.
  43. [Protective effect of selank on the model of mnestic function violation induced by pharmacological blockade of protein synthesis]. Eksperimental’naia i klinicheskaia farmakologiia, 2013.
  44. [Compensatory effect of selank on the mnestic functions disturbed by neurotoxic damage of the noradrenergic system of the rat brain]. Eksperimental’naia i klinicheskaia farmakologiia, 2008.
  45. Effect of selank on cognitive processes after damage inflicted to the cerebral catecholamine system during early ontogeny. Bulletin of Experimental Biology and Medicine, 2007.
  46. Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content in the Hippocampus and Prefrontal Cortex in Rats. Bulletin of Experimental Biology and Medicine, 2019.
  47. Intranasal administration of the peptide Selank regulates BDNF expression in the rat hippocampus in vivo. Doklady Biological Sciences, 2008.
  48. Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats. Behavioural Neurology, 2017.
  49. The Influence of Selank on the Level of Cytokines Under the Conditions of “Social” Stress. Current Reviews in Clinical and Experimental Pharmacology, 2021.
  50. Efficacy of peptide anxiolytic selank during modeling of withdrawal syndrome in rats with stable alcoholic motivation. Bulletin of Experimental Biology and Medicine, 2014.
  51. Selank, a Peptide Analog of Tuftsin, Attenuates Aversive Signs of Morphine Withdrawal in Rats. Bulletin of Experimental Biology and Medicine, 2022.
  52. [Comparison of pharmacological effects of heptapeptide selank after intranasal and intraperitoneal administration to BALB/c and C57BL/6 mice]. Eksperimental’naia i klinicheskaia farmakologiia, 2016.
  53. Anticoagulant Effects of Arginine-Containing Peptides of the Glyproline Family (His-Phe-Arg-Trp-Pro-Gly-Pro and Thr-Lys-Pro-Arg-Pro-Gly-Pro) Revealed by Thromboelastography. Bulletin of Experimental Biology and Medicine, 2017.
  54. [Effects of the new peptide anxiolytic drug selank on the cardiovascular system functioning and respiration in cats]. Eksperimental’naia i klinicheskaia farmakologiia, 2005.
  55. Sedative-Hypnotic Agents That Impact Gamma-Aminobutyric Acid Receptors: Focus on Flunitrazepam, Gamma-Hydroxybutyric Acid, Phenibut, and Selank. Journal of Clinical Pharmacology, 2021.
  56. Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives. International Journal of Molecular Sciences, 2026.
  57. The occurrence of putative cognitive enhancing research peptides in seized pharmaceutical preparations: An incentive for controlling agencies to prepare for future encounters of the kind. Drug Testing and Analysis, 2020.